Orthofix Medical Inc. reports third quarter net sales of $205.6 million and net loss of $22.8 million
Reuters
Nov 04
Orthofix Medical Inc. reports third quarter net sales of $205.6 million and net loss of $22.8 million
Orthofix Medical Inc. reported third quarter 2025 net sales of $205.6 million, including sales from M6 artificial cervical and lumbar discs. Pro forma net sales, excluding M6 discs, were $203.4 million, up 5% on a reported basis and 6% on a pro forma constant currency basis compared to the third quarter of 2024. U.S. Spine Fixation net sales grew 8%, with procedure volume growth of 10% over the same period last year. The company reported a net loss of $22.8 million, or $0.57 per share. Non-GAAP pro forma adjusted EBITDA for the quarter was $24.6 million, a 28.2% increase compared to the prior year. Orthofix updated its full-year 2025 guidance by narrowing its net sales outlook while maintaining the midpoint and raising the low end of its adjusted EBITDA guidance. The company expects positive free cash flow for full-year 2025, excluding restructuring charges related to the discontinuation of the M6 product lines.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orthofix Medical Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251104386716) on November 04, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.